ArticleCommunications medicine2026
Mathematical modeling of the population-level impact of hypothetical herpes simplex virus type 2 curative therapy.
Article in Communications medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHerpes simplex virus type 2 (HSV-2) infection is a prevalent lifelong infection and the leading cause of genital ulcer disease (GUD), yet no vaccines or curative interventions are currently available. Emerging curative approaches have demonstrated proof-of-concept efficacy in preclinical studies, but their potential population-level impact remains unknown. This study assessed the potential impact of curative therapy on HSV-2 disease burden and transmission.
methodsA dynamic HSV-2 transmission model was developed for the United States and calibrated to prevalence estimates from the National Health and Nutrition Examination Surveys. Curative therapy was assumed to be introduced in 2030 and scaled to 20%, 50%, or 80% coverage by 2040 under two scenarios: (i) treatment of symptomatic individuals only and (ii) treatment of all individuals with HSV-2 infection.
resultsHere we show that, by 2050, at 80% coverage, curative therapy for symptomatic individuals reduces the number of 15-49-year-olds with GUD and GUD days by 86.7% and 86.2%, respectively, and decreases the incidence rate and annual new infections by 54.0% and 51.7%, averting 5.4 million cumulative infections. The numbers needed to treat to avert one prevalent or incident symptomatic HSV-2 infection, one incident HSV-2 infection, and one year of GUD days are 0.90, 3.4, and 0.61, respectively.
conclusionsCurative therapy could substantially reduce HSV-2 incidence and recurrent GUD, yielding population-level benefits beyond individual cure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.